Privia Health's Accountable Care Organizations achieved $233.1 million in shared savings for 2024, a 32% increase from 2023, managing over $2.5 billion in healthcare benchmark spend across 3,280 providers serving approximately 194,700 Medicare beneficiaries.

Privia Health reported strong Q2 2025 financial performance with 23.4% revenue growth, raised full-year guidance, and expanded to 5,125 implemented providers across 15 states.

Privia Health Group, Inc. reported strong financial results for the first quarter of 2025, with increases in revenue, gross profit, operating income, and net income. The company also announced its expansion into the state of Arizona through a partnership with Integrated Medical Services, one of the largest independent multi-specialty practices in the state.

Privia Health Group, Inc. (Nasdaq: PRVA) announced that it will release its fourth quarter and full-year 2024 financial results on February 27, 2025, and host a conference call to discuss the results.

The U.S. primary care physicians market is expected to grow by $46.15 billion from 2022-2027, driven by demographic shifts, healthcare access, and the increasing prevalence of chronic diseases. Key trends include telehealth integration, patient-centered medical homes, and digital health adoption.

Privia Health to Participate in the William Blair Growth Stock Conference

Ratings for Privia Health Gr (NASDAQ:PRVA) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 3 2 0 0 Analysts have set 12-month price targets for Privia Health Gr, revealing an average target of $26.42, a high estimate of $37.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.92%. Decoding Analyst Ratings: A Detailed Look The standing of Privia Health Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jailendra Singh Truist Securities Lowers Buy $24.00 $28.00 Richard Close Canaccord Genuity Lowers Buy $26.00 $37.00 Craig Jones Stifel Lowers Buy $24.00 $28.00 Daniel Grosslight Citigroup Announces Buy $25.00 - Richard Close Canaccord Genuity Lowers Buy $37.00 $41.00 Lisa Gill JP Morgan Lowers Overweight $30.00 $38.00 Andrew Mok Barclays Announces Equal-Weight $22.00 - Andrew Mok UBS Lowers Buy $29.00 $31.00 Gary Taylor TD Cowen Lowers Outperform $26.00 $30.00 Jailendra Singh Truist Securities Lowers Buy $28.00 $32.00 Elizabeth Anderson Evercore ISI Group Lowers Outperform $25.00 $26.00 Adam Ron B of A Securities Lowers Neutral $21.00 $27.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions ...Full story available on Benzinga.com

DH vs. PRVA: Which Stock Is the Better Value Option?

The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 4.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Privia Health Reports First Quarter 2024 Financial Results, Reiterates Full Year 2024 Guidance

During the last three months, 9 analysts shared their evaluations of Privia Health Gr (NASDAQ:PRVA), revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 3 2 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $27.0, a high estimate of $37.00, and a low estimate of $21.00. A decline of 15.99% from the prior average price target is evident in the current average. Interpreting Analyst Ratings: A Closer Look In examining recent analyst actions, we gain insights into how financial experts perceive Privia Health Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Daniel Grosslight Citigroup Announces Buy $25.00 - Richard Close Canaccord Genuity Lowers Buy $37.00 $41.00 Lisa Gill JP Morgan Lowers Overweight $30.00 $38.00 Andrew Mok Barclays Announces Equal-Weight $22.00 - Andrew Mok UBS Lowers Buy $29.00 $31.00 Gary Taylor TD Cowen Lowers Outperform $26.00 $30.00 Jailendra Singh Truist Securities Lowers Buy $28.00 $32.00 Elizabeth Anderson Evercore ISI Group Lowers Outperform $25.00 $26.00 Adam Ron B of A Securities Lowers Neutral $21.00 $27.00 Key Insights: Action Taken: Analysts respond to ...Full story available on Benzinga.com